WORCESTER, Mass., March 4, 2010 (GLOBE NEWSWIRE) -- In September of 2009, Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced that the United States Food and Drug Administration (FDA) had approved the treatment use of Generex Oral-lyn® under the FDA's Expanded Access Treatment Investigational New Drug (IND) Program. Generex Oral-lyn® is the Company's proprietary buccal insulin spray product for the treatment of patients with Type 1 or Type 2 diabetes mellitus, impaired glucose tolerance (IGT), or pre-diabetes. The product is presently in a global Phase III pivotal clinical trial in patients with Type 1 diabetes mellitus.
